
On Thursday, Skye Bioscience Inc. (NASDAQ:SKYE) reported positive results from two preclinical obesity studies testing nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody.
In the first study, nimacimab matched or exceeded the weight loss of Novo Nordisk's (NYSE:NVO) monlunabant while showing superior post-treatment maintenance.